Aphria生产能力高，国际业务广泛。星座品牌的收购为Canopy Growth带来优势。在未来一年，Aphria可能会超过Canopy Growth，但从长远来看，Canopy Growth更有可能成为更大的赢家。
If you had a time machine, there's no question which stock you'd go back in time to buy with a choice between Aphria and Canopy Growth . Aphria has delivered a lifetime return that would have multiplied your initial investment more than 13 times. But Canopy Growth's share price has soared even more.
如果你有一台时间机器，毫无疑问，你会选择在 Aphria 和 Canopy Growth 之间及时买回哪只股票。Aphria 实现了终生回报，这将使您的初始投资增加13倍以上。但 Canopy Growth 的股价更是飙升了。
I'm going to assume, though, that you don't have a time machine. Choosing between Aphria and Canopy Growth isn't as easy without the benefit of hindsight. Which of these top marijuana stocks is more likely to be the bigger winner in the future? Here's how Aphria and Canopy stack up against each other.
不过，我想假设你没有时间机器。如果没有后见之明的好处，选择 Aphria 和 Canopy Growth 并不容易。这些顶尖的大麻股票中，哪种更有可能成为未来更大的赢家？这里是 Aphria 和 Canopy 如何相互堆积。
Aphria has been through the wringer over the last few months. The company faced allegations that it drastically overpaid for its LATAM Holdings acquisition. Its CEO stepped down. Aphria even had to fight off a hostile takeover attempt. But you could make a pretty good argument that Aphria has emerged from all of this in better shape than ever.
在过去的几个月里，Aphria经历了这个磨难。该公司因收购 LATAM Holdings 而被指支付过高价格。它的首席执行官辞职了。Aphria 甚至不得不抵制敌意收购。但你可以提出一个非常好的论点，即 Aphria 已经在所有这些方面出现了比以往更好的形式。
While a special committee comprised of independent directors on Aphria's board of directors found that the company hadn't overpaid for its LATAM acquisition, one side effect of the investigation was that Aphria has improved its governance processes. The company also has a strong interim CEO in Irwin Simon -- who previously served as CEO of organic food company Hain Celestial -- while it searches for a full-time CEO.
尽管 Aphria 董事会中由独立董事组成的一个特别委员会发现，该公司收购 LATAM 的资金没有过高，但调查的一个副作用是 Aphria 改进了治理流程。该公司还在欧文•西蒙( Irwin Simon )担任了一位强有力的临时首席执行官，此前他曾担任有机食品公司 Hain Celestial 的首席执行官。
Although Aphria's board rebuffed a takeover bid by U.S.-based cannabis company Green Growth Brands, the acquisition attempt helped draw attention to Aphria's strengths. One of those strengths is the company's production capacity. Aphria thinks that it will have an annual production capacity of 255,000 kilograms by the end of 2019. The recent licensing of its Aphria One facility expansion definitely helped the company in achieving that goal.
尽管 Aphria 董事会拒绝了总部位于美国的大麻公司 Green Growth Brands 的收购要约，但这一收购努力帮助人们关注了 Aphria 的优势。这些优势之一是公司的生产能力。Aphria 认为，到2019年底，其年产能将达到25.5万公斤。最近对 Aphria One 工厂的许可扩张无疑帮助该公司实现了这一目标。
Aphria has supply agreements in place with all of Canada's provinces plus the Yukon territory. It partnered with Southern Glazer's, the largest wine and spirits distributor in North America, to distribute its adult-use recreational marijuana products across Canada.
Aphria 与加拿大所有省份以及育空地区签订了供货协议。它与北美最大的葡萄酒和烈酒分销商 Southern Glazer 公司合作，在加拿大销售成人娱乐用大麻产品。
The company also has extensive international operations. Aphria is acquiring its German partner, CC Pharma, which distributes products to more than 13,000 pharmacies in Germany. It owns one of seven cannabis import licenses in Italy. Aphria owns 25% of Australian medical cannabis producer Althea. The company has a joint venture in Lesotho. And there's the LATAM Holdings acquisition, which gives Aphria access to medical marijuana markets in Colombia, Argentina, Jamaica, and possibly Brazil.
该公司还拥有广泛的国际业务。Aphria 正在收购其德国合作伙伴 CC Pharma ，该公司向德国1.3万多家药店分销产品。它在意大利拥有七个大麻进口许可证之一。Aphria 拥有澳大利亚医用大麻生产商 Althea 25%的股份。该公司在莱索托有一家合资企业。还有 LATAM 控股公司的收购，这使 Aphria 有机会进入哥伦比亚、阿根廷、牙买加和巴西的医用大麻市场。
Aphria's historical sales don't justify its market cap of around $2.4 billion. However, the stock trades at a discount to several of its peers when you factor in Aphria's production capacity and growth prospects.
Aphria 的历史销售额不足以证明其24亿美元的市值。不过，如果将 Aphria 的生产能力和增长前景考虑在内，该公司股票的交易价格低于几家同行。
查看大麻股Canopy相关分析，点击下方阅读全文
閱讀更多 匯眾醫療 的文章
